Holen Sie sich die Stockscreener-App
25.29
0.04%
0.010
Handel nachbörslich:
25.32
0.03
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.28
Offen:
$25.18
24-Stunden-Volumen:
42.90M
Relative Volume:
0.69
Marktkapitalisierung:
$143.79B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
14.74
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
+1.57%
1M Leistung:
-1.86%
6M Leistung:
-1.29%
1J Leistung:
-5.85%
1-Tages-Spanne:
$25.12
$25.56
1-Wochen-Bereich:
$24.83
$26.00
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.29 | 143.73B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,085.19 | 991.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
205.75 | 499.90B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.13 | 412.54B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.99 | 269.55B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.46 | 272.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Citi Keeps Their Hold Rating on Pfizer (PFE) - The Globe and Mail
What margin trends mean for Pfizer Inc. stockExit Point & Fast Moving Stock Watchlists - ulpravda.ru
Pfizer Turns To AI Where Drug Risk Is Highest - TradingView — Track All Markets
Pfizer Partners with Boltz to Use AI in Drug Discovery - TradingView — Track All Markets
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks - Finviz
How Pfizer Inc. stock performs in high volatility marketsWeekly Profit Summary & Momentum Based Trading Ideas - ulpravda.ru
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks - The Motley Fool
Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy Biomolecular Ai Foundation Models - MarketScreener
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns - TechStock²
Pfizer, Boltz Launch Collaboration to Develop Biomolecular AI Foundation Models - MarketScreener
Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment - Finviz
Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy State-of-the-Art Biomolecular AI Foundation Models - PR Newswire
PFIZER INC : Berenberg remains Neutral - MarketScreener
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity - Business Wire
Does Pfizer (PFE) Offer Long Term Value After A 36% Three Year Share Price Slide - simplywall.st
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43 - simplywall.st
Pfizer's (NYSE:PFE) Dividend Will Be $0.43 - Yahoo Finance
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026? - Nasdaq
Pneumococcal Vaccines Market to Boom Worldwide By 2026-2033 | - openPR.com
Is Pfizer Inc PFE stock undervalued historicallyQuarterly Earnings Report & Proven Capital Preservation Tips - moha.gov.vn
Thousands Sue Pfizer Over Claims That Birth Control Caused Brain Tumors - iHeart
PFIZER INC : UBS withdraws its Sell rating - MarketScreener
Alert from law firm on Pfizer Depo-Provera MDL trial date withdrawn - MarketScreener
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio - Bluefield Daily Telegraph
This Could Be Key to Pfizer's Turnaround in 2026 - Finviz
Bayer takes Pfizer and BioNTech to court over COVID vaccines - MarketScreener
Pfizer’s Scottish RSV Maternal Vaccine Study: What Investors Should Watch - TipRanks
Pfizer's Gandsman Takes Zeno Post - O'Dwyer's PR
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk - ts2.tech
Vitiligo Market Set for Robust Expansion Through 2034, DelveInsight Reports | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech - The Globe and Mail
Pfizer needs more than obesity deal to drive growth post-2028, UBS says - Investing.com Canada
Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines - MarketScreener
Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure (NYSE:PFE) - Seeking Alpha
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties - Law360
Bayer sues COVID vaccine makers over mRNA technology - Reuters
December Social Media Round-Up—2025 Highlights, YaoPharma Co., Ltd. Global Collaboration, and More - Pfizer
Is Pfizer (PFE) Offering Value After Recent Share Price Weakness? - Yahoo Finance
Pfizer Stock Plot Twist: Is This Big Pharma OG a Secret Comeback Play or Total Trap? - AD HOC NEWS
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Pfizer invested in this Peninsula biotech startup. Now they've cut a potentially big drug deal - The Business Journals
Cartography Biosciences And Pfizer To Collaborate On The Discovery Of Tumor-Selective Antigens - TradingView — Track All Markets
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens - Business Wire
Torray Investment Partners LLC Acquires 102,107 Shares of Pfizer Inc. $PFE - MarketBeat
Sulfasalazine Market Is Booming Worldwide 2026-2033 | Pfizer - openPR.com
Robeco Institutional Asset Management B.V. Has $290.44 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Phenobarbital Market See Incredible Growth 2025-2032 | Sanofi, Pfizer Inc., Novartis AG, H. Lundbeck A/S - openPR.com
Pfizer's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Gateway Investment Advisers LLC Lowers Stock Position in Pfizer Inc. $PFE - MarketBeat
Sleep Aids Market Booming with Rapid Growth Through 2033| Pfizer Inc., GSK plc, Sommetrics, Inc. - openPR.com
Pfizer’s 2026 Drug Price Reset Could Be A Game Changer For Pfizer (PFE) - simplywall.st
Pfizer (PFE) Stock: COVID-19 Revenue Decline Spurs Strategic Shift - parameter.io
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.96%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):